Track KNSA and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Kiniksa Pharmaceuticals Ltd
105 Piccadilly, London, United Kingdom, W1J 7NJ
IPO
2018
Employees
366
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q2 20265-5
0
Q1 20267-7
0
Q4 20258-8
0
3-quarter cumulative
20 sells0 buys
Analyst Ratings
2 analysts covering
Buy100%recommend buy
Buy
2
Hold
0
Sell
0